Investor Meeting on Q2 FY2019 Results



Shigeo Taniuchi

President & Chief Operating Officer

Kazuo Koshiji

Senior Corporate Officer, Corporate Administration, Chief Financial Officer

Naveed Shams, M.D., Ph.D.

Senior Corporate Officer, Chief Scientific Officer

November 7, 2019

Copyright© 2019 Santen Pharmaceutical Co., Ltd. All rights reserved.

Forward-Looking Statements

Santen

- Information given in this presentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts.
- Business performance and financial condition are subject to the effects of medical regulatory changes made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
- The process of drug research and development from discovery to final approval and sales is long, complex and uncertain. Individual compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the non-approval of products after a regulatory filing has been submitted. Forecasts and projections concerning new products take into account assumptions concerning the development pipelines of other companies and any co-promotion agreements, existing or planned. The success or failure of such agreements could affect business performance and financial condition significantly.
- Business performance and financial conditions could be affected significantly by a substantial drop in sales of a major drug, either currently marketed or expected to be launched, due to termination of sales as a result of factors such as patent expiry and complications, product defects or unforeseen side effects. Santen Pharmaceutical also sells numerous products under sales and/or manufacturing license from other companies. Business performance could be affected significantly by changes in the terms and conditions of agreements and/or the non-renewal of agreements.
- Santen Pharmaceutical is reliant on specific companies for supplies of certain raw materials used in production. Business performance could be affected significantly by the suspension or termination of supplies of such raw materials if such and event were to adversely affect supply capabilities for related final products.



Santen's Values and Mission Statement

Values




¹ "Exploring the secrets and mechanisms of nature in order to contribute to people's health"

Santen's original interpretation of a passage from chapter 22 of Zhongyong (The Doctrine of the Mean) by Confucius.

We think carefully about what is essential, decide clearly what we should do, and act quickly.

Mission Statement By focusing on ophthalmology, Santen develops unique scientific knowledge and organizational capabilities that contribute to the well-being of patients, their loved ones and consequently to society.



Number of People Visually Impaired in the World

Vision is the Most Dominant of Our Senses

we contribute to improve the QOL of patients around the world

As a specialized company focusing on ophthalmology,

Major factors associated with increasing number of people with visual impairment


Source: WHO World report on vision: https://www.who.int/publications-detail/world-report-on-vision

Santen

MTP2020 Fundamental Policy and Strategic Goals



Responding to the needs of patients and medical professionals worldwide, Santen will achieve reliable growth while sustainably contributing to ophthalmic treatment worldwide



Santen

Core OP

[JPY billions]

■ 1st half revenue up 3.9%, profit (core basis) up 6.2% YoY

Q2 FY2019 Highlights


Robust 1st half results and steady progress toward achieving the full-year forecast

Global ophthalmology business activities

Partnership with Glaukos

Raise strength / efficiency of business framework

Implementation of Management Frame Work




Revenue

[JPY billions]

FY2019 Forecast (No Change from May 9)

Aiming for further growth and efficiency improvements




Santen

7

FY2019 Dividend Forecast

Increase dividend by JPY1 to JPY27 (forecast)

- Stable and sustainable return to shareholders
- Mid and Long term strategic investment for growth beyond 2020
 - → Implementing shareholder return policies to achieve the best balance between above two priorities considering dividends and total return



* Total return forecast for FY2019 does NOT include the potential impact from future share buyback





Q2 FY2019 Financial Results ended September 30, 2019

Q2 FY2019 Results

Strong overseas sales led revenue and profit growth (core basis)

(JPY billions)	FY2018	FY2019		
	Q2	Q2		
Core basis	Actual	Actual	YoY	
Revenue	114.3	118.8	118.8 3.9%	
COGS	45.8	48.3 5.5%		
Gross margin	68.6	70.5	2.8%	
SG&A	33.5	33.4 -0.2		
R&D expenses	11.0	11.4	4.1%	
OP	24.1	25.6	6.2%	
Net profit	17.8	18.8 5.6%		
IFRS				
OP	20.8	19.0	-8.7%	
Net profit	14.4	13.1	-8.7%	
USD	110.21	108.82		
EUR	129.81	121.28		
CNY	16.70	15.77		

Revenue

Japan: Steady growth of key products *Overseas*: Maintain strong growth, particularly in Asia and China

⇒Increase by JPY4.4 billion (+3.9%)

Core operating profit

- Steady growth of overseas business
- Increase profits by cost optimization

⇒Increase by JPY1.5 billion (+6.2%)

IFRS operating profit and net profit

Temporary expenses increased due to the start of DE-128 amortization, and review of the timing and accuracy of milestone payments through development progress and business alliances.

Operating profit \Rightarrow Decreased by JPY1.8 billion (-8.7%)


Net profit \Rightarrow Decreased by JPY1.2 billion (-8.7%)



Q2 FY2019 Revenue



Double-digit sales growth in overseas (local currency basis) drove group sales



<u>Japan</u>

- Prescription Pharmaceuticals: Steady growth driven by *Eylea*** (+9.7%) and *Diquas* (+11.6%)
- OTC: Despite steady sales of premium products for the domestic market, revenue decreased due to sluggish overseas tourists' demands
- Surgical: *LENTIS Comfort,* newly launched in April providing comfortable vision in long and intermediate distance contributed to revenue

<u>Overseas</u>

- Asia : Strong sales in each country and region (JPY basis: China +17.1%, Korea +14.5%, Local currency basis: China +24.0%, South Korea +24.7%)
- EMEA* : Revenue increased 11.5% in € basis, while increased 4.1% in JPY due to the appreciation of JPY against €. *Tapcom* is driving growth.

EMEA*: Including export to North America etc. Eylea**: Co-promoted product of Bayer Yakuhin, Ltd. (MAH)

Q2 FY2019 Income Statement



Revenue and profits (core basis) increased, however profits (IFRS) declined mainly due to DE-128 amortization.


	Q2 Fነ	(18	Q2 F	Y19		
(JPY billions)	Actual	vs Revenue	Actual	vs Revenue	YoY	
Revenue	114.3		118.8		3.9%	
COGS	45.8	40.0%	48.3	40.7%	5.5%	
Gross margin	68.6	60.0%	70.5	59.3%	2.8%	
SG&A expenses	33.5	29.3%	33.4	28.1%	-0.2%	
R&D expenses	11.0	9.6%	11.4	9.6%	4.1%	Impact of starting amortization of
Core operating profit	24.1	21.1%	25.6	21.6%	6.2%	DE-128: +1.4
Amortization on intangible assets assosiated with products	3.5	3.0%	4.9	4.2%	42.1%	
Other income	0.3	0.2%	0.2	0.1%	-38.1%	Revaluation of InnFocus contingent payment: +1.2
Other expenses	0.1	0.1%	1.9	1.6%		
Operating profit (IFRS)	20.8	18.2%	19.0	16.0%	-8.7%	
Finance income	0.5	0.5%	0.5	0.4%	-5.3%	
Finance expenses	1.6	1.4%	1.1	0.9%	-29.1%	
Profit before tax	19.8	17.3%	18.4	15.5%	-7.0%	Since tax effect cannot be recognized on the expense from the change in the fair value of contingent payment (described above), income tax expense would not be
Income tax expenses	5.4	4.7%	5.3	4.4%	-2.5%	
Actual tax ratio	27.4%		28.7%			
Net profit (IFRS)	14.4	12.6%	13.1	11.1%	-8.7%	reduced, resulting in an increase in actual
Core net profit	17.8	15.6%	18.8	15.8%	5.6%	tax rate.



Status of Research & Development

Q2 FY2019 Research and Development Highlights

Steady progress to expand the pipeline





Santen

The Current Status of Research and Development

Pipeline/product Development (1)

As of October, 2019 Updated information is underlined

	Indication	Region	Status	
DE-111 <i>TAPCOM / TAPTIQOM</i> Combination of tafluprost and timolol maleate	Glaucoma / ocular hypertension	China	P3 Plan: FY2020 P3 completion	
DE-117 <i>EYBELIS</i> EP2 receptor agonist	Glaucoma / ocular hypertension	US	P3 Plan: FY2020 P3 completion	
		Japan	Launched	
		Asia	Filed Plan: FY2020 approval	
DE-126 FP/EP3 receptors dual agonist	Glaucoma / ocular hypertension	US	P2b	
		Japan	FZD	
DE-128 PRESERFLO MicroShunt	Glaucoma	US	P2/3 Plan: FY2019 PMA rolling submission completion, FY2020 launch	
		Europe	CE mark received	
DE-130A Catioprost latanoprost	Glaucoma / ocular hypertension	Europe	P3	
		Asia	Plan: FY2021 P3 completion	



The Current Status of Research and Development

Pipeline/product Development (2)

	Indication	Region	Status	
		US	P3 Plan: FY2022 P3 completion	
DE-109	Uveitis	Japan	P3	
IVT sirolimus		Europe	P3	
		Asia	Filed	
DE-122 Anti-endoglin antibody	Wet age-related macular degeneration	US	P2a Plan: FY2019 P2a completion	
		Europe	Launched	
DE-076C Vekacia / Verkazia Vernal kerato-con	Vernal kerato-conjunctivits	Asia	Approved of expanded indication to Ikervis in Aug 2019 in Taiwan	
ciclosporin		Others	Approved, Plan: FY2019 launch	
DE-114A epinastine HCI (high dose)	Allergic conjunctivitis	Japan	<u>Approved in Sep 2019</u> Plan: <u>Nov 2019 NHI price listing and launch soon after</u>	
DE-127 Myopia	Japan	Started P2/3 in Aug 2019 Plan: FY2023 P2/3 completion		
	Asia	P2 Plan: FY2019 P2 completion		
MD-16 Intraocular lens	Cataract	Japan	Filed Plan: FY2019 approval	

16



As of October, 2019


Updated information is underlined



Appendix


Q2 FY2019 Financial Position


Santen



Q2 FY2019 Revenue (Japan)








[Surgical]


Q2 FY2019 Revenue (Asia)





Q2 FY2019 Revenue (EMEA*)






EMEA*: Including export to North America etc.

Q2 FY2019 Revenue by Area






EMEA (Billion JPY) 12% Cosopt 4.6 3.2 Tapros 19% Ikervis 1.4 63% Others 9.2 Total 18.4

Asia (Ex. China)





16%

Eylea*: Co-promoted product of Bayer Yakuhin, Ltd. (MAH)

<u>China</u>

